Eyenovia (NASDAQ:EYEN) Earns “Hold” Rating from Brookline Capital Management

Eyenovia (NASDAQ:EYEN)‘s stock had its “hold” rating reaffirmed by research analysts at Brookline Capital Management in a research note issued to investors on Friday,Benzinga reports.

A number of other equities research analysts have also commented on the company. William Blair restated a “market perform” rating on shares of Eyenovia in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a research note on Wednesday.

Eyenovia Price Performance

Shares of NASDAQ:EYEN traded down $0.23 during trading hours on Friday, hitting $0.11. 38,368,520 shares of the company’s stock traded hands, compared to its average volume of 1,382,547. Eyenovia has a 52 week low of $0.09 and a 52 week high of $2.57. The company has a market cap of $6.91 million, a price-to-earnings ratio of -0.14 and a beta of 1.75. The company’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.71. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.27 and a current ratio of 0.74.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the previous year, the company posted ($0.18) EPS. As a group, equities analysts anticipate that Eyenovia will post -0.56 EPS for the current fiscal year.

Insider Activity at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe purchased 50,000 shares of the stock in a transaction dated Monday, August 26th. The shares were bought at an average cost of $0.57 per share, with a total value of $28,500.00. Following the completion of the transaction, the chief executive officer now owns 82,927 shares in the company, valued at $47,268.39. This trade represents a 151.85 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eyenovia in the 2nd quarter valued at approximately $26,000. Ground Swell Capital LLC bought a new stake in Eyenovia in the second quarter valued at about $27,000. Nations Financial Group Inc. IA ADV lifted its stake in Eyenovia by 24.4% during the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares during the period. Financial Management Network Inc. acquired a new stake in Eyenovia during the third quarter valued at approximately $39,000. Finally, SkyView Investment Advisors LLC acquired a new stake in Eyenovia during the second quarter valued at approximately $87,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.